The treatment algorithm of mCRC patients is tailored according to three major points, i.e patient characteristics (performance status, comorbidities, age, previous adjuvant treatment, preferences, acceptance of toxicities and expectations); tumour characteristics (metastatic burden, potential resectabity and sites of metastasis, primary tumour location) and molecular profile (RAS genes/BRAF status, microsatellite instability and, eventually, HER2 overexpression and NTRK rearrangement). This evidence concerns the gene BRAF and neoplasm.